Case Discussion: Lower Disease Burden with Brain Metastases

This case-based episode examines a younger, active patient with EGFR exon 19–mutant metastatic NSCLC, bilateral lung involvement, and small, asymptomatic brain metastases. Despite low symptom burden, the presence of CNS disease drives a strong preference for CNS-active combination regimens to avoid or delay brain radiation and improve long-term intracranial control. The discussion then turns practical, detailing deployment of the “cocoon” dermatologic regimen, strict sun protection, and prophylactic anticoagulation to mitigate thrombotic risk with amivantamab-based therapy. Early dose interruptions and stepwise reductions are framed as proactive strategies to manage skin and other toxicities while preserving long-term benefit. This episode offers a detailed look at how clinical features and patient values interface with toxicity management in frontline EGFR-mutant disease.